Science Weekly Science Weekly

Can a world-first gene therapy reverse ageing?

Jul 16, 2026 · 18m

Summary

This episode explores a groundbreaking trial by Life Biosciences using Yamanaka factors to rejuvenate retinal cells in patients with age-related eye disease. Hosts Madeleine Finlay and Ian Sample discuss how epigenetic reprogramming could reverse cellular aging, potentially treating age as a disease. They interview Professor Paul Knopfler, who highlights the risks of tumor formation and the current focus on safety in this first-in-human study.

Topics discussed

Introduction: Reversing biological time and cellular rejuvenation Life Biosciences trial for age-related eye disease Cellular aging: DNA damage, mitochondria, and epigenetics Understanding epigenetic markers and their role in cell identity Yamanaka factors and induced pluripotent stem cells Risks of reprogramming: Teratoma cancers and loss of cell identity The ER100 gene therapy trial and David Sinclair's involvement Safety concerns and expert skepticism on trial efficacy Future implications: Treating aging as a disease Conclusion and credits

More from Science Weekly

Could measles and midterms bring down Maha?
Nov 19, 2026
Nasa’s Voyager 1 probe in sight of an incredible milestone
Nov 17, 2026
Is BMI working? Cop31 latest, the science of great conversation
Nov 12, 2026
Why we get Sad and what helps
Nov 10, 2026
‘Ferritin face’: can you really diagnose low iron from a selfie?
Nov 5, 2026
Listen ad-free on Castria